Communiqué de presse
U.S. Food and Drug Administration Approves Nivolumab + Ipilimumab Combined with Limited Chemotherapy as First-Line Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer
In CheckMate -9LA, nivolumab + ipilimumab combined with two cycles of chemotherapy demonstrated superior overall survival versus chemotherapy, regardless […]